Last $0.03 USD
Change Today +0.002 / 6.67%
Volume 135.6K
UVFT On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

uv flu technologies inc (UVFT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/14 - $0.09
52 Week Low
12/31/13 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UV FLU TECHNOLOGIES INC (UVFT)

Related News

No related news articles were found.

uv flu technologies inc (UVFT) Related Businessweek News

No Related Businessweek News Found

uv flu technologies inc (UVFT) Details

UV Flu Technologies, Inc. is engaged in the research, development, manufacture, and sale of air purification systems and products primarily in the United States. Its flagship product, the ViraTech UV-400, utilizes high-intensity germicidal ultraviolet radiation inside a killing chamber that goes beyond filtering to trap and destroy harmful microbes. The company also offers RX Air product line, which include HEPA based air purifiers. Its products are used in hair and nail salons, pet kennels, test labs, hospitals, restaurants, casinos, and military installations. The company was formerly known as Northwest Chariots Incorporated and changed its name to UV Flu Technologies, Inc. in November 2009. UV Flu Technologies, Inc. was founded in 2006 and is based in Yarmouthport, Massachusetts.

3 Employees
Last Reported Date: 01/13/14
Founded in 2006

uv flu technologies inc (UVFT) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

uv flu technologies inc (UVFT) Key Developments

UV Flu Technologies, Inc. Announces Amendment and Restatement of Bylaws

On June 17, 2014, the Board of Directors of UV Flu Technologies agreed to amend and restate the Bylaws of UV Flu, effective immediately. The amendments are: clarifying that notices of shareholder meetings may be given by electronic transmission; amending the shareholders' action without a meeting provision to enable any action that could be taken by shareholders at a meeting to be taken without such a meeting, prior notice or vote if written consent(s) are signed by the required majority of shareholders. The previous provision required a consent to be signed by all shareholders who would have been eligible to vote on the relevant matter; removing provisions requiring proxy appointments to be signed so as to enable electronic proxies; broadening the scope of forms of communication that can be used for shareholder and Board meetings beyond forms which are similar to a conference telephone; and correcting typographical errors and to make certain non-substantive, stylistic changes as reflected in the Amended and Restated Bylaws.

UV Flu Technologies, Inc. Enters into Marketing Partnership with myVBO

UV Flu Technologies, Inc. entered a marketing partnership with myVBO. UVFT is partnering with myVBO, a company that brings unique sales and marketing experience to businesses of all sizes, to provide internet optimization, marketing, advertising and brand management designed to build the ViraTech and RxAir brands, as well as support multi-channel sales distribution. Through its website, brand development and marketing work and sales channel development with Better Rest Solutions, myVBO has proven success in driving sales in the medical device industry.

UV Flu Technologies, Inc. Enters into Master Distribution Agreement with Universal Consumer Electronics Systems, LLC

UV Flu Technologies, Inc. has entered into a master distribution agreement with Universal Consumer Electronics Systems, LLC (UCES) for exclusive worldwide distribution of all UVFT products. The partnership with UCES will expand exposure and access to UVFT's air purification systems. They are joining in a collaborative effort to identify quality products in the healthcare and electronics industries and provide the strategic direction, distribution, marketing and sales services that will position the products at the top of their industries. UCES works in close partnership with myVBO, which executes the complementary marketing, advertising and internet optimization strategies for select clients. The UV-400 incorporates unique filterless UV technology that kills greater than 99% of airborne bacteria on first pass and eliminates other infectious agents, improving the quality of life for people who suffer from autoimmune disorders, allergies and other health conditions. As part of the three-year agreement, UCES is subject to sales quotas of 36,000 units per year from October 1, 2014 through September 30, 2015 (subject to a four-month ramp up), and 50,000 units annually (October 1 through September 30) thereafter. UVFT will receive a flat fee plus cost for worldwide retail sales (including internet sales direct to customer) of ViraTech units. For all RxAir products distributed wholesale, UVFT will earn a percentage of the profits that will fluctuate dependent upon whether UVFT or UCES primarily sources the vendor.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UVFT:US $0.03 USD +0.002

UVFT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.31 USD +0.42
Honeywell International Inc $94.90 USD +0.62
Sears Holdings Corp $38.93 USD +0.58
View Industry Companies

Industry Analysis


Industry Average

Valuation UVFT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UV FLU TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at